Predictive value of pediatric thrombosis diagnoses in the Danish National Patient Registry

Ruta Tuckuviene1
Soeren Risom Kristensen1
Jon Helgestad2
Anette Luther Christensen1
Soeren Paaske Johnsen3
1Department of Clinical Biochemistry, Center for Cardiovascular Research,
2Department of Pediatrics,
3Department of Clinical Epidemiology, Aarhus University Hospital, Aalborg and Aarhus, Denmark

Abstract: Data on the validity of pediatric thrombosis diagnoses are missing. We aimed to examine the predictive value of a diagnosis of venous and arterial thrombosis using the Danish National Patient Registry (DNPR). We identified all first-time diagnoses among children and adolescents (aged 0–18 years) between 1994 and 2006 in DNPR. In total, 1138 potential cases of thrombosis were identified; the medical records were retrieved for 1112 (97.7%) and the positive predictive value (PPV) computed. Overall, the diagnosis of thrombosis was verified in 598 of the 1112 cases, corresponding to a PPV of 53.7% (95% confidence interval [CI]: 50.8–56.7). Diagnoses from wards had the PPV of 62.5% (95% CI: 59.4–65.6). The predictive value of a thrombosis diagnosis from wards was age-dependent, with a higher PPV (77.4%, 95% CI: 68.7–84.7) in neonates (<28 days) and adolescents (15–18 years) (68.2%; 95% CI: 63.2–72.5)) than in children (28 days–14 years) (51.2%; 95% CI: 46.0–56.4)). The PPV of a thrombosis diagnosis was improved by restricting the analysis to diagnoses from wards, primary diagnoses, and admissions with a length of stay of three or more days. The results indicate that an interpretation of nonvalidated hospital discharge data for pediatric thrombosis in a registry like DNPR should be made with caution.

Keywords: pediatric thrombosis, discharge diagnosis, registry, positive predictive value

Introduction
Thromboembolic disease, including both arterial and venous thrombosis, is generally uncommon in children but impacts mortality, chronic morbidity, and childhood development. The incidence of pediatric thromboembolism seems to increase in parallel with diagnostic and therapeutic advances and decreased mortality in children with primary critical illnesses.1

Administrative databases and medical registries are often used in epidemiological research and access to such data sources is almost mandatory when conducting large-scale epidemiological studies of rare diseases, including pediatric thromboembolism. However, all data, including data from registries, need to be valid in order to avoid misleading results. Validation studies of thrombosis diagnoses in children are lacking, though there are several studies on the quality of registry data for arterial12–13 and venous thromboembolism in adults.14–18 The aim of the present study was to determine the positive predictive value (PPV) of arterial and venous thrombosis diagnoses for 0 to 18-year-old individuals in the Danish National Patient Registry (DNPR).

Material and methods
The Danish National Health Service provides free, tax-supported health care to the entire population of Denmark.19 Information on discharges from Danish hospitals

1 Department of Clinical Biochemistry, Center for Cardiovascular Research, Aalborg Hospital, Aarhus University Hospital, Høbrovej 18-22, 9000 Aalborg, Denmark
Tel +45 9932 3309
Fax +45 9813 1196
Email rt@m.dk

This article was published in the following Dove Press journal:
Clinical Epidemiology
2 June 2010
Number of times this article has been viewed
is available in the Danish National Patient Registry, which contains data on all discharges since 1977 and all outpatients since 1995.\textsuperscript{20} The data include the dates of admission and discharge, surgical procedure(s) performed, and up to 20 diagnoses classified according to the International Classification of Diseases (ICD; 8th revision until the end of 1993 and the 10th revision thereafter). Discharge diagnoses in the registry are determined exclusively by the physician, who discharges the patient.

All incident cases in children and adolescents with a first-time discharge diagnosis of arterial and/or venous thrombosis were identified in the DNPR. We only included patients who were 0–18 years old and residents of Denmark at the time of admission. The study period was restricted to January 1, 1994 through December 31, 2006. The ICD-10 diagnosis codes of thrombosis and number of recorded diagnoses in the DNPR are presented in Table 1.

**Criteria for diagnoses**

A diagnosis of thrombosis was confirmed if documented by clinical presentation and supported by findings from imaging, surgery, or autopsy. The presence of clinical signs was mandatory for confirming a diagnosis. The detailed clinical presentation of thrombosis in different age groups was reported previously.\textsuperscript{21–23} We considered the following definitions of thrombosis:

- Cerebral sinovenous thrombosis (CSVT): any transient neurological dysfunction and thrombosis of the cerebral veins or venous sinuses demonstrated by computed tomography (CT), magnetic resonance (MR) scan, MR venography, and/or conventional cerebral venography.
- Pulmonary embolism (PE): dyspnea, chest pain, hypoxia, and cardiac-respiratory collapse combined with findings from ventilation-perfusion lung scan, CT, or pulmonary angiography.
- Deep venous thrombosis (DVT): swelling, pain, and discoloration of the extremities or vena cava superior syndrome or renal and/or liver dysfunction, and ultrasonography ULS/venography/CT/MR findings in agreement with thrombosis.
- Arterial ischemic stroke (AIS): clinical presentation consistent with stroke (ie, neurological deficits, seizures, lethargy, or abnormalities in muscle tone) and a CT scan or MR showing a focal ischemic infarct of a location and age consistent with the neurological signs and symptoms. Patients with primary cerebral hemorrhage not associated with AIS or CSVT were excluded.
- Thrombosis in the arteries of limbs, abdomen, and thorax: ischemia of the limb or selected organ dysfunction supported by findings from contrast angiography/Doppler ultrasonography/CT/MR or surgery. Thrombosis in stents and arteriovenous grafts were not included.
- Myocardial infarction (MI): symptoms supported by electrocardiogram (ECG) and biochemical markers or findings on coronary angiography.
- Retinal occlusion: visual problems confirmed by ophthalmoscopic examination or by positive findings on angiography/CT/MR.

<table>
<thead>
<tr>
<th>Thrombosis localization</th>
<th>ICD-10 diagnosis codes</th>
<th>Number of first-time diagnoses recorded in the DNPR n (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Venous</td>
<td>Cerebral sinovenous</td>
<td>I67.6, I63.6, G0.8</td>
</tr>
<tr>
<td></td>
<td>Retinal veins</td>
<td>H34.8</td>
</tr>
<tr>
<td></td>
<td>Pulmonary embolism</td>
<td>I26</td>
</tr>
<tr>
<td></td>
<td>Vena cava, renal veins, hepatoporal veins</td>
<td>I81–I82</td>
</tr>
<tr>
<td></td>
<td>Deep veins of extremities</td>
<td>I80.1–I80.9</td>
</tr>
<tr>
<td></td>
<td>Venous thrombosis in relation to pregnancy</td>
<td>O22.5A, O87.3, O22.3, O22.8–9, O87A–F, O87.1</td>
</tr>
<tr>
<td>Arterial</td>
<td>Ischemic stroke</td>
<td>I63–I64</td>
</tr>
<tr>
<td></td>
<td>Retinal arteries</td>
<td>H34.1–H34.2</td>
</tr>
<tr>
<td></td>
<td>Arteries of extremities and/or aorta</td>
<td>I74</td>
</tr>
<tr>
<td></td>
<td>Renal arteries</td>
<td>N28.0A, N28.0D</td>
</tr>
<tr>
<td></td>
<td>Myocardial infarction</td>
<td>I21</td>
</tr>
<tr>
<td>Miscellaneous (combined arterial and venous)</td>
<td>Mesenterial</td>
<td>K55.0H, K55.0C</td>
</tr>
<tr>
<td></td>
<td>Retinal</td>
<td>H34, H34.9</td>
</tr>
<tr>
<td>All</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
Medical record review

Medical records were retrieved and reviewed by a single experienced pediatrician (RT) using a detailed standardized form developed in collaboration with local and international consultants in pediatric hematology/oncology with pediatric thrombosis experience. Cerebral and noncerebral thromboses were registered in separate forms, focusing on symptoms and date of symptoms, imaging, location of the thrombosis, dates of diagnosis and treatment, possible causes of not confirming the diagnosis in DNPR, choice and effect of treatment, risk factors and outcome (Appendices A, B). The review was based on all available information in the medical records, including results from laboratory tests (coronary biomarkers), ECG, and radiology reports. The actual imaging films were not re-interpreted, and the assessment was based on written reports by a radiologist. The reviewer was not blinded to the registered discharge codes.

Ethics

The study was approved by the Danish Data Protection Agency (J. no. 2007-41-0539) and the National Board of Health (J. no. 7-604-04-2/37/EHE).

Statistical analysis

The PPV of the thrombosis diagnoses recorded in the DNPR was calculated as a proportion; the numerator was the number of patients with a confirmed diagnosis after a review of the medical records and the denominator was the total number of patients registered with a specific diagnosis. The PPV was calculated for all patients and separately for neonates (<28 days old) including preterm born neonates (<gestational week 37 + 0), children (28 days–14 years old), adolescents (15–18 years old), and specific diagnostic categories. Preterm born children aged 28 days–14 years at the time of thrombosis were attributed to the age group “children”. Data were also stratified by sex, type of hospital department (emergency room or ward, including outpatient clinic), length of stay (shorter vs 3 days or longer), type of diagnosis (primary or secondary), type of hospital (university vs regional), and calendar periods (1994–1999, 1999–2002, and 2003–2006). The estimation of 95% confidence intervals (CI) was based on an approximation of the PPV to binomial distribution. Data were analyzed using STATA statistical software version 10.

Results

Thrombosis diagnoses in the DNPR

A total of 1138 individuals aged 0–18 years residing in Denmark were recorded with a first-time diagnosis of thrombosis in the DNPR during the period 1994–2006 (Table 1). We were able to retrieve and review medical records from 1112 (97.7%) of these patients.

Diagnostic tools for diagnosing thrombosis

Diagnostic tools used to confirm different types of thrombosis are presented in Table 2. MR imaging was used to confirm CSVT diagnosis in 84.2% of CSVT cases and AIS in 68.9% of AIS cases. The remaining cerebral thromboses were documented by CT. Ultrasonography was used to evaluate 214 of 259 patients (82.6%) with verified diagnoses of DVT, whereas contrast angiography alone was used in 30 of 259 cases (11.6%; Table 2). Findings from coronary angiography

Table 2 Diagnostic tools for verified diagnosis of symptomatic thrombosis

<table>
<thead>
<tr>
<th>Diagnostic method</th>
<th>Venous thrombosis</th>
<th>Arterial thrombosis</th>
<th>Retinal occlusion</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>CSVT</td>
<td>DVTb</td>
<td>PE</td>
</tr>
<tr>
<td>MR (± CT)</td>
<td>n=38</td>
<td>n=259</td>
<td>n=48</td>
</tr>
<tr>
<td></td>
<td>n (%)</td>
<td>n (%)</td>
<td>n (%)</td>
</tr>
<tr>
<td>CT alone</td>
<td>32 (84.2)</td>
<td>9 (3.5)</td>
<td>1 (2.1)</td>
</tr>
<tr>
<td>Ultrasonography</td>
<td>6 (16.2)</td>
<td>9 (3.5)</td>
<td>10 (20.8)</td>
</tr>
<tr>
<td>Ventilation-perfusion lung scan (± other tools)</td>
<td>–</td>
<td>–</td>
<td>34 (70.8)</td>
</tr>
<tr>
<td>Angiography alone</td>
<td>–</td>
<td>30 (11.6)</td>
<td>1 (2.1)</td>
</tr>
<tr>
<td>Autopsy</td>
<td>–</td>
<td>–</td>
<td>1 (2.1)</td>
</tr>
<tr>
<td>Miscellaneousa</td>
<td>–</td>
<td>–</td>
<td>1 (2.1)</td>
</tr>
</tbody>
</table>

Notes: aMiscellaneous diagnostic tools are i) findings during surgery (PE and arterial thrombosis), ii) biochemical markers and/or electrocardiogram findings in MI, iii) ophthalmoscopic examination in retinal occlusion. bMethod of examination was unknown in one patient with DVT in the extremities and abdomen. cType of brain scan was unknown in one patient with AIS. dTwo newborns were included based on clinical signs of a threatened limb. Imaging or surgery was not performed.

Abbreviations: AIS, arterial ischemic stroke; CT, computed tomography; CSVT, cerebral sinovenous thrombosis; DVT, deep venous thrombosis; MI, myocardial infarction; MR, magnetic resonance; PE, pulmonary embolism.
Supported the diagnosis of MI in two patients, whereas typical changes in ECG were seen in one MI case and autopsy findings confirmed the diagnosis in a fourth child.

Positive predictive values

A thrombosis diagnosis was confirmed in 598 of 1112 patients, corresponding to an overall PPV of 53.7% (95% confidence interval [CI]: 50.8–56.7). When diagnoses recorded in emergency departments were excluded (n = 176), the PPV increased 62.5% (95% CI: 59.4–65.6) (Table 3). All diagnoses in neonates were made at wards, while 44 of 419 children and 132 of 578 adolescents had diagnoses from emergency departments. The PPV of diagnoses among adolescents and children was 54.7% (95% CI: 50.5–58.8) and 46.1% (95% CI: 41.2–51.0), respectively, and increased substantially among adolescents when emergency room diagnoses were excluded (Table 3). Focusing at diagnoses from wards, no major differences in PPV between the diagnostic categories was found, except for diagnosis of MI (Table 3). Variation in the PPV was seen in some specific thrombosis diagnoses from wards between the three age groups (Table 3). Predictive values of a thrombosis diagnosis from wards were age-dependent, with the highest PPV in neonates, and the PPV in adolescents higher than in children. The PPV among children were lower for venous thromboses and tended to be higher for AIS than in adolescents (Table 3).

The PPV of diagnoses from wards also differed according to length of hospital stay (shorter vs 3 days or longer), and to type of diagnosis (primary vs secondary) (Table 4). In contrast, no differences in the PPV were found according to gender, different study periods or type of hospital (university vs regional) (Table 4).

Almost half of the identified thrombosis diagnoses (514/1112) in the DNPR were not confirmed after the validation process. The main cause (67.9%) for not being confirmed was the absence of findings consistent with thrombosis on imaging.

<table>
<thead>
<tr>
<th>Diagnoses</th>
<th>PPV% (95% CI)a, nconfirmed/n_totalb</th>
<th>All departments</th>
<th>Emergency departments</th>
<th>Wards Total</th>
<th>Neonates (&lt;28 days)</th>
<th>Children (28 days–14 years)</th>
<th>Adolescents (15–18 years)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total</td>
<td>53.7 (50.8–56.7)</td>
<td>598/1112</td>
<td>7.4 (13.5–11.3)</td>
<td>62.5 (59.4–65.6)</td>
<td>77.4 (68.7–84.7)</td>
<td>51.2 (46.0–56.4)</td>
<td>68.2 (63.6–72.5)</td>
</tr>
<tr>
<td>All venous thrombosisd</td>
<td>53.9 (50.0–57.8)</td>
<td>345/640</td>
<td>7.4 (3.6–13.2)</td>
<td>65.3/10/135</td>
<td>82.4 (65.5–93.2)</td>
<td>39.0 (30.4–48.2)</td>
<td>74.4 (69.5–78.9)</td>
</tr>
<tr>
<td>CSVT</td>
<td>66.7 (52.9–78.6)</td>
<td>38/57</td>
<td>0/2</td>
<td>69.1 (55.2–80.9)</td>
<td>87.5 (47.4–99.7)</td>
<td>50.0 (29.1–70.9)</td>
<td>82.6 (61.2–95.1)</td>
</tr>
<tr>
<td>PE</td>
<td>47.5 (37.5–57.7)</td>
<td>48/101</td>
<td>0/25</td>
<td>62.2 (51.3–73.9)</td>
<td>7/8</td>
<td>12/24</td>
<td>19/23</td>
</tr>
<tr>
<td>Thrombosis of vena cava, renal veins, hepatoportal veins</td>
<td>62.8 (52.6–72.1)</td>
<td>64/102</td>
<td>9.1 (0.3–41.3)</td>
<td>69.2 (58.7–78.7)</td>
<td>94.7 (74.0–99.9)</td>
<td>52.8 (35.5–69.6)</td>
<td>72.2 (54.8–85.8)</td>
</tr>
<tr>
<td>DVT in extremities</td>
<td>51.3 (46.2–56.5)</td>
<td>195/380</td>
<td>9.3 (4.3–16.9)</td>
<td>65.7 (59.9–71.2)</td>
<td>50.0 (11.8–88.2)</td>
<td>29.4 (17.5–43.8)</td>
<td>74.3 (68.1–79.9)</td>
</tr>
<tr>
<td>All arterial thrombosisd</td>
<td>53.6 (49.0–58.2)</td>
<td>253/472</td>
<td>7.3 (15.4–19.9)</td>
<td>58.0 (53.2–62.7)</td>
<td>75.3 (64.5–84.2)</td>
<td>57.1 (50.8–63.3)</td>
<td>45.9 (35.8–56.3)</td>
</tr>
<tr>
<td>AIS</td>
<td>58.1 (52.8–63.2)</td>
<td>209/360</td>
<td>4.6 (1.2–22.8)</td>
<td>61.5 (56.1–66.8)</td>
<td>73.9 (61.5–84.0)</td>
<td>62.3 (55.3–68.9)</td>
<td>47.0 (34.6–59.7)</td>
</tr>
<tr>
<td>Thrombosis in arteries of the extremities, aorta</td>
<td>62.7 (49.2–75.0)</td>
<td>37/59</td>
<td>25.0 (0.6–80.6)</td>
<td>65.5 (51.4–77.8)</td>
<td>92.3 (64.0–99.8)</td>
<td>59.1 (36.4–79.3)</td>
<td>55.0 (31.5–76.9)</td>
</tr>
<tr>
<td>Myocardial infarction</td>
<td>10.5 (2.9–24.8)</td>
<td>4/38</td>
<td>7.7 (0.2–36.0)</td>
<td>12.0 (2.6–31.2)</td>
<td>50.0 (1.3–98.7)</td>
<td>12.5 (1.6–38.4)</td>
<td>0/7</td>
</tr>
<tr>
<td>Retinal occlusions</td>
<td>20.0 (4.3–48.1)</td>
<td>3/15</td>
<td>0/2</td>
<td>23.1 (5.0–53.8)</td>
<td>0/1</td>
<td>0/7</td>
<td>60.0 (14.7–94.7)</td>
</tr>
</tbody>
</table>

Notes: a95% confidence interval. bNumber of confirmed diagnoses/number of recorded diagnoses. Including cerebral sinovenous thrombosis (CSVT), pulmonary embolism (PE), and deep venous thrombosis (DVT) in the extremities and miscellaneous veins. Including arterial ischemic stroke (AIS), thrombosis in the arteries of limbs and aorta, myocardial infarction (MI), and retinal occlusions. dOne arterial, one venous, one bland.

Abbreviation: CI, confidence interval.
tests or a lack of imaging required to support the diagnosis of thrombosis (Table 5). An imaging test was not performed in 94 of 380 patients registered with a discharge diagnosis of DVT in the extremities and in 36 of 101 recorded PE diagnoses. Imaging confirmed primary cerebral hemorrhage was found in 7.5% of the patients registered with a diagnosis of AIS. Coding errors, defined as inaccuracies in coding the discharge diagnosis or incorrect data entry into a registry, were seen overall in 20.6% of possible thrombosis diagnoses. An accidental incorrect data entry was particularly frequent for rare diagnoses in children, specifically MI, retinal occlusion, and CSVT (Table 5).

Discussion

We found that only 53.7% of all pediatric thrombosis diagnoses registered in the DNPR could be confirmed after a review of the medical records. However, the registry also includes diagnoses from emergency rooms, and stratification by hospital departments increased the overall PPV, in particular the PPV among adolescents. The highest predictive values were associated with discharge diagnosis from a ward, primary diagnoses, a hospital stay of three or more days, and diagnoses made in neonates and adolescents.

To the best of our knowledge, the present study is the first to evaluate the quality of pediatric thrombosis diagnoses in an administrative registry. In adults, a PPV of 74%–84% has been reported for VTE and 65%–97% for arterial thromboembolism, including ischemic stroke and coronary disease. These validation studies are essential in epidemiological and clinical studies of thrombosis; however, the results can not be

### Table 4

The positive predictive value (PPV) of discharge diagnoses of venous and arterial thrombosis in the subgroup of in-patients (0–18 years) in the Danish National Patient Registry (DNPR)

<table>
<thead>
<tr>
<th>Subgroups</th>
<th>n</th>
<th>PPV% (95% CI)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Male</td>
<td>400</td>
<td>62.5 (57.6–67.3)</td>
</tr>
<tr>
<td>Female</td>
<td>536</td>
<td>62.5 (58.3–66.6)</td>
</tr>
<tr>
<td>Primary diagnosis</td>
<td>615</td>
<td>66.8 (63.0–70.5)</td>
</tr>
<tr>
<td>Secondary diagnosis</td>
<td>321</td>
<td>54.2 (48.6–59.8)</td>
</tr>
<tr>
<td>Hospital stay &lt;3 days</td>
<td>334</td>
<td>44.6 (39.2–50.1)</td>
</tr>
<tr>
<td>Hospital stay ≥3 days</td>
<td>602</td>
<td>72.4 (68.7–76.0)</td>
</tr>
<tr>
<td>University hospitals</td>
<td>354</td>
<td>64.4 (59.2–69.4)</td>
</tr>
<tr>
<td>Regional hospitals</td>
<td>582</td>
<td>61.3 (57.3–65.3)</td>
</tr>
</tbody>
</table>

**Study periods:**
- 1999–2002: 278 (63.0 (57.0–68.6))
- 2003–2006: 337 (63.2 (57.8–68.4))

**Abbreviations:** n, recorded diagnoses in DNPR; CI, confidence interval.

### Table 5

Unconfirmed thrombosis diagnoses

<table>
<thead>
<tr>
<th>Registered thrombosis diagnosis</th>
<th>Total</th>
<th>Asymptomatic course</th>
<th>Lack of confirmation from imaging</th>
<th>Incorrect code</th>
<th>Miscellaneous a</th>
</tr>
</thead>
<tbody>
<tr>
<td>CSVT n = 57</td>
<td>19</td>
<td>0</td>
<td>7 (36.8)</td>
<td>9 (47.4)</td>
<td>3 (15.8)</td>
</tr>
<tr>
<td>PE n = 101</td>
<td>53</td>
<td>2 (3.8)</td>
<td>41 (77.4)</td>
<td>8 (15.1)</td>
<td>2 (3.8)</td>
</tr>
<tr>
<td>Thrombosis of vena cava, renal veins, hepatoportal veins n = 102</td>
<td>38</td>
<td>6 (15.8)</td>
<td>20 (52.6)</td>
<td>8 (21.1)</td>
<td>4 (10.6)</td>
</tr>
<tr>
<td>DVT in extremities n = 380</td>
<td>185</td>
<td>1 (0.5)</td>
<td>157 (84.9)</td>
<td>26 (14.1)</td>
<td>1 (0.5)</td>
</tr>
<tr>
<td>AIS n = 360</td>
<td>151</td>
<td>6 (4.0)</td>
<td>102 (67.6)</td>
<td>23 (15.2)</td>
<td>20 (13.3)</td>
</tr>
<tr>
<td>Thrombosis in arteries of the extremities, aorta n = 59</td>
<td>22</td>
<td>1 (4.6)</td>
<td>14 (63.6)</td>
<td>4 (18.2)</td>
<td>3 (13.6)</td>
</tr>
<tr>
<td>MI n = 38</td>
<td>34</td>
<td>0</td>
<td>6 (17.7)</td>
<td>19 (55.9)</td>
<td>9 (26.5)</td>
</tr>
<tr>
<td>Retinal occlusions n = 15</td>
<td>12</td>
<td>1 (8.3)</td>
<td>2 (16.7)</td>
<td>8 (66.7)</td>
<td>1 (8.3)</td>
</tr>
<tr>
<td>Total</td>
<td>514</td>
<td>17 (3.3)</td>
<td>349 (67.9)</td>
<td>105 (20.4)</td>
<td>43 (8.4)</td>
</tr>
</tbody>
</table>

**Notes:** aMiscellaneous causes for exclusion: i) diagnosis before or after study period, ii) thrombosis in stents (n = 2 arterial noncerebral), iii) diagnosis of thrombosis due to meningococcal infection (n = 1 arterial noncerebral), iv) lack of supporting ophthalmoscopic findings in retinal occlusions and biochemical markers and/or electrocardiogram findings in MI.

**Abbreviations:** AIs, arterial ischemic stroke; CSVT, cerebral sinovenous thrombosis; DVT, deep venous thrombosis; MI, myocardial infarction; PE, pulmonary embolism.
extrapolated to thrombosis studies in children. The epidemiology and pathophysiology of thromboembolic disease in children is vastly different from what is seen in adults. Differences in the coagulation system during childhood and a constellation of endogenous and exogenous thrombophilic risk factors in children make pediatric thrombosis unique. In particular, neonates should be considered a separate population, different from older children, and several thromboembolic diseases, such as ischemic arterial stroke, are not comparable to AIS in adults.\textsuperscript{25} Therefore, results from studies in adults can not be generalized to studies of thrombosis in children.

A few studies have examined the quality of pediatric diagnoses in administrative databases. Diagnoses in children in the DNPR were examined in 1995 as a whole (no specification of diseases) and the PPV found to be 73.3%.\textsuperscript{26} Recently, pediatric diagnoses of asthma and febrile seizures in the DNPR were described to have high predictive values of 85.0% and 92.8%, respectively.\textsuperscript{26,27} Furthermore, the PPV of childhood cancer diagnoses was estimated to be 97.1% in the nationwide Danish Cancer Registry.\textsuperscript{28} In contrast, the overall PPV of diagnoses of thrombosis from wards in our study was much lower, only 62.5%. Thus, the diagnoses of thromboembolic diseases in the registry are more uncertain than diagnoses of cancer, febrile seizures, and asthma. However, the PPV of more homogenous groups and specific diagnoses in certain age groups (eg, VTE and CSVT in newborns with a PPV of 82.4%) were comparable to the other validation studies of pediatric diagnoses.

The population in our study was divided into three groups: neonates (<28 days), children (28 days–14 years), and adolescents (15–18 years). The relatively high PPV of diagnoses in newborns probably reflects their treatment in subspecialized neonatal divisions of pediatric departments. Children younger than 15 years of age are normally admitted directly to the pediatric departments in the hospitals taking care of all acute admissions, whereas adolescents older than 15 years of age are administratively assigned to adult wards. Emergency room diagnoses represent mostly “suspected” diagnoses, whereas the subsequent diagnostic steps and treatment are performed in the ward. We found a PPV of 7.4% for pediatric thrombosis diagnoses from emergency rooms. A low predictive value of thrombosis diagnoses from emergency rooms has also been reported among adults.\textsuperscript{1,11,17} A variation of 2.5%–90% in the agreement between diagnosis groups from clinical and administrative data sources has been found in pediatric emergency departments.\textsuperscript{29} However, thrombosis diagnoses were not among the diagnoses in that study. To the best of our knowledge, the low validity of emergency room diagnoses of pediatric thrombosis was not reported previously, and the findings might be important when conducting further studies.

Generally, there was no disagreement between the diagnosis in the medical records and the conclusion of our record review. The most common cause of nonconfirmed diagnoses was situations when suspicion of thrombosis was raised, but the diagnosis was ruled out by the objective examination or by imaging. In such situations, a code “observation for thrombosis” is supposed to be used but was not. Thus, the major cause of nonconfirmed diagnoses was incorrect coding rather than incorrect diagnostic work-up and diagnosis.

A wide range of medical conditions was identified among the cases where cerebral thrombosis could not be verified, including hypoxic–ischemic encephalopathy due to perinatal asphyxia, Todd’s paralysis, intracerebral hemorrhage, migraine, and severe headache. Few patients with a diagnosis of arterial ischemic stroke had thrombosis in cerebral veins. When noncerebral thrombosis was ruled out, no alternative diagnosis could be made in the majority of cases. In some cases, however, a different diagnosis was made by the physician, such as rupture of muscle fiber or superficial thrombophlebitis instead of DVT, and muscle pain or hyperventilation rather than PE.

The quality of data from administrative registries can be affected by errors in the data set. In our study, incorrect data entry was seen according to individual diagnosis codes in the DNPR and found in half of the recorded diagnoses of AMI (“121” instead of “Q21” for congenital heart disease) and retinal occlusion (“H34” instead of “B34” for unspecific virus infection).

**Strengths and limitations**

Our study has the strength that it is based on the whole population in a country; thus, the findings are representative of the nationwide registry. The estimated incidence of symptomatic VTE and AIS in children is 0.07/10,000 and 0.1/10,000 person years, respectively.\textsuperscript{30,31} Thus, only large multi-center studies or population-based studies are able to assemble the epidemiological data required for the interpretation of the results. Our study was based on all first-time diagnoses of thrombosis in 0–18-year-old individuals over 13 years in a country with 5.5 million inhabitants.\textsuperscript{32} All residents have a unique personal registration number, which ensured a valid linking of information between the DNPR and medical records. Diagnoses in the registry were according to ICD-10, and all possible thrombosis diagnoses were identified in the examination in order to not miss...
any cases of thrombosis in the DNPR; for example, additional diagnoses of thrombosis in relation to pregnancy in teenage girls were included in the search, but none were found. The retrieval of medical records for possible thrombosis diagnoses was nearly complete; only 26 of 1138 records could not be found. The confirmation of thrombosis diagnosis was based on available information in the medical records, which may not be a perfect gold standard; however, we found the clinical information to be detailed and properly documented.

However, there are also some limitations to our study. Finding a thrombus in the imaging results without any symptoms (screening) was not considered a criterion for the verification of a diagnosis in our study. Overall, 1.5% of identified diagnoses (17/1112) were found to be asymptomatic. Additionally, two children had thrombi in stents and were not included in the analysis. These factors reduced the calculated PPV, but only to a minimal degree.

All records were reviewed by the same person. Therefore, the decisions are consistent, but they also rely on the judgment of this person. However, the forms that were used to make the judgments were developed in collaboration with other experienced clinicians, and all uncertain cases were discussed.

In our study we have not been able to assess the sensitivity, completeness and negative predictive value of DNPR because we had no method to track cases not registered in the DNPR. The vast majority of pediatric patients with such a severe disease are likely to be hospitalized, however, thrombosis diagnoses may be missed in the DNPR if the thrombosis is not considered to be a secondary diagnosis in a severe course of a complex disease (eg, pediatric cancer). An independent data source (eg, a pediatric thrombosis registry) would be needed in order to get further insights into the accuracy of the DNPR.

In conclusion, the overall positive predictive values of pediatric thrombosis diagnoses were low to moderate. The PPV might be improved by restricting the data to diagnoses from wards, patients with primary diagnoses, and admissions with a length of stay of 3 days or more. Thus, the use and interpretation of nonvalidated data on pediatric thromboembolism from the DNPR should only be done with caution.

Disclosure
The authors report no conflicts of interest in their work.

References


Appendix A

Cerebral thrombosis in children

Date of collection: ………/…………/……………..
Hospital: …………
Department: …………
Patient ID number: …………………………………….

______________________________________________________________________________

1. Symptoms: □ yes □ no □ unknown
□ seizures □ n.facialis paresis
□ altered mental status □ hemiparesis
□ other …………………………………………………

Date of start of symptoms: ………/………/…………… □ unknown

______________________________________________________________________________

2. Imaging performed: □ yes □ no □ unknown
□ CT ± angio ……………………… confirming thrombosis: □ yes □ no □ unknown
□ MR ± angio ……………………… confirming thrombosis: □ yes □ no □ unknown □ other
………………………………………… confirming thrombosis: □ yes □ no □ unknown

______________________________________________________________________________

3. Pt. included: □ yes □ no
If not, cause: □ no symptoms □ no radiologic findings □ error in coding □ other

______________________________________________________________________________

4. Location of thrombosis i CNS:
□ arterial □ right side
□ venous □ left side
Arterial CNS thrombosis:
□ a. cerebri media □ a. basilaris
□ a. vertebralis □ other ……………………………………………

Venous CNS thrombosis:
□ sinus sagitalis superior □ internal veins
□ sinus transversus □ other ……………………………………………

Presence of simultaneous hemorrhage: □ yes □ no □ unknown

______________________________________________________________________________

5. Date of diagnosis of thrombosis: ………/………/…………… □ unknown

______________________________________________________________________________

6. Antithrombotic treatment: □ yes □ no □ unknown
□ LMWH
Medication: ………………………………………………… □ unknown
Dose/kg/day: ……………………….. □ unknown
Date of start: ………/………/…………… □ unknown
Date of completion: ………/………/…………… □ no □ unknown
□ UFH
Dose/kg/day: ……………………….. □ unknown
Date of start: ………/………/…………… □ unknown
| Date of completion: ........../........./......................... □ no □ unknown |
| □ Aspirin |
| Dose/kg/day: ................./......................... □ unknown |
| Date of start: ........../........./......................... □ unknown |
| Date of completion: ........../........./......................... □ no □ unknown |
| □ Warfarin |
| Date of start: ........../........./......................... □ unknown |
| Date of completion: ........../........./......................... □ no □ unknown |
| □ Other |
| Medication: ................................................ □ unknown |
| Date of start: ........../........./......................... □ unknown |
| Date of completion: ........../........./......................... □ no □ unknown |

7. Monitoring of LMWH treatment by P-antifactor Xa
 □ yes □ no □ unknown

8. Bleeding during antithrombotic treatment: □ yes □ no □ unknown
Location: ................................................ □ unknown
Immediate intervention needed: □ yes □ no □ unknown
Blood transfusion needed due to bleeding during antithrombotic treatment: □ yes □ no □ unknown

9. Other complications to antithrombotic treatment: □ yes □ no □ unknown
If yes, describe: .................................................................

10. SVT resolution examined: □ yes □ no □ unknown
If yes,
 □ CT ± angio
 □ MR ± angio
SVT resolution: ........../........./............. □ yes □ no
 □ completely □ partial □ unknown

11. Neurological sequelae after 1 year (± 3 months): □ yes □ no □ unknown
 □ epilepsy □ motor impairment/disability □ cognitive problems
 □ other: .................................................................

**Risk factors**

12. Did pt. experience thrombosis before: □ yes □ no □ unknown
If yes, date of 1. thrombosis: ........../........./............. □ unknown
Location of 1. thrombosis: ................................................ □ unknown
Prophylactic antithrombotic treatment after 1. thrombosis: □ yes □ no □ unknown
If yes, medication: .................................................................
Completed: □ yes □ no □ unknown
If yes, date of completion: ........../........./......................... □ unknown
13. Disposition:
Parents or siblings with thrombosis: □ yes □ no □ unknown
Documented inherited thrombophilia in parents or siblings: □ yes □ no □ unknown
If yes, describe: ……………………………………………………………………………………………

14. Underlying cancer: □ yes □ no □ unknown
If yes, diagnosis: □ leukemia/lymphoma □ CNS tumor □ other
Protocol of treatment: ………………………………………………………………… □ unknown
Phase of treatment during thrombosis: ………………………………………………………………… □ unknown
Treatment with asparaginase by the occurrence of thrombosis: □ yes □ no □ unknown
Last dose of asparaginase before thrombosis: ………/……/…… □ unknown
Type of asparaginase:
□ Erwinase □ E. coli asparaginase □ PEG asparaginase □ unknown
Asparaginase stopped/dose decreased due to thrombosis? □ yes □ no □ unknown

15. Treatment by occurrence of thrombosis:
Steroids: □ yes □ no □ unknown
(□ prednisolone □ prednisone □ dexamethasone □ other)
TPN: □ yes □ no □ unknown
Oral contraceptive: □ yes □ no □ unknown

16. Varicella infection before AIS: □ yes □ no □ unknown
If yes, date: ………/………… □ unknown

17. Infection by the time of admission: □ yes □ no □ unknown
Type: ………………………………………………………………… □ unknown
Antibiotic treatment: □ yes □ no □ unknown
Fever >37.5: □ yes □ no □ unknown

18. CVL: □ yes □ no □ unknown
Date of the last insertion: ………/……/………… □ unknown
Type: □ subcutane port □ extern tunneled □ extern untunneled □ unknown
Location: □ yes □ unknown
If yes,
□ right-sided □ OE
□ left-sided □ UE
Vein: ………………………………………………………………… □ unknown
CVL removed: □ yes □ no □ unknown
Cause:
□ thrombosis □ infection □ other
19. Arterial catheter: □ yes □ no □ unknown
   Date of insertion: ..…/……/………………………….. □ unknown
   Artery: ………………………………………………... □ unknown

20. Risk factors within 3 months
    yes no unknown
    Surgery
    Immobilization (≥4 days)
    Trauma

21. Other underlying diseases: □ yes □ no □ unknown
    If yes, describe: …………………………………………………………………………..

22. Thrombophilia:
    No work-up: □ yes → end of scheme

<table>
<thead>
<tr>
<th>Tested</th>
<th>yes</th>
<th>no</th>
<th>unknown</th>
</tr>
</thead>
<tbody>
<tr>
<td>Protein C</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Protein S</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Antithrombin</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Fibrinogen</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Lupus anticoagulant</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Cardiolipin antibodies IgM</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Cardiolipin antibodies IgG</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Beta-2-glycoprotein-1 IgM</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Beta-2-glycoprotein-1 IgG</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Activated protein C resistance</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Factor V mutation Leiden G1691A</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Factor II mutation G20210A</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Homocysteine</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Lipoprotein(a)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Factor VIII</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Documented defect: □ yes □ no □ unknown
    If yes, describe: …………………………………………………………………………..
Appendix B

Noncerebral thrombosis in children

Date of collection: ………/…………/……………
Hospital: …………………
Department: …………
Patient ID number: ………………………………………….

1. Symptoms: □ yes □ no □ unknown
Date of start of symptoms: ………/…………/…………… □ unknown

2. Imaging performed: □ yes □ no □ unknown
□ ULS ± Doppler ……………………… confirming thrombosis: □ yes □ no □ unknown
□ Contrast veno/arteriography ……………. confirming thrombosis: □ yes □ no □ unknown
□ CT ± angio ……………………… confirming thrombosis: □ yes □ no □ unknown
□ MR ± angio ……………………… confirming thrombosis: □ yes □ no □ unknown

3. Pt. included: □ yes □ no
If no, reason: □ no symptoms □ no radiologic findings □ error in coding □ other

4. Location of thrombosis:

Venous thrombosis: □ yes
□ DVT in UE □ v. cava inferior □ v. cava superior
□ v. iliaca □ v. lienalis □ intracard right
□ v. femoralis □ v. portae □ v. subclavia
□ v. mesenterica □ v. hepatica □ v. jugularis
□ v. renalis □ PE
□ other ………………………………………………………………………………………………

Arterial thrombosis: □ yes
□ a. femoralis □ a. mesenterica □ intracard left
□ a. iliaca □ a. renalis □ a. retinae
□ aorta abdominalis □ a. hepatica □ a. brachialis
□ other ………………………………………………………………………………………………

Side: □ yes □ no □ unknown
If yes,
□ right
□ left

5. Date of diagnosis: ………/…………/…………… □ unknown

6. Antithrombotic treatment: □ yes □ no □ unknown
□ LMWH
Medication: ……………………………………………………………………………………………… □ unknown
Dose/kg/day: ……………………………………………………………………………………………… □ unknown
Date of start: ………/…………/…………… □ unknown
Date of completion ………/…………/…………… □ no □ unknown
UFH
Dose/kg/day: ........................................... □ unknown
Date of start: ........../........./............ □ unknown
Date of completion ........../........./............ □ no □ unknown

Aspirin
Dose/kg/day: ........................................... □ unknown
Date of start: ........../........./............ □ unknown
Date of completion ........../........./............ □ no □ unknown

Warfarin
Date of start: ........../........./............ □ unknown
Date of completion ........../........./............ □ no □ unknown

Other
Medication: ................................................................. □ unknown
Date of start: ........../........./............ □ unknown
Date of completion ........../........./............ □ no □ unknown

7. Monitoring of LMWH treatment by P-antifactor Xa
□ yes □ no □ unknown

8. Embolectomy: □ yes □ no □ unknown

9. Bleeding during antithrombotic treatment: □ yes □ no □ unknown
Location: ................................................................. □ unknown
Immediate intervention needed: □ yes □ no □ unknown
Blood transfusion needed due to bleeding during antithrombotic treatment: □ yes □ no □ unknown

10. Other complications of antithrombotic treatment: □ yes □ no □ unknown
If yes, describe: .................................................................

11. Resolution examined: □ yes □ no □ unknown
□ ULS ± Doppler
□ contrast venography
□ MR ± angio
□ CT ± angio
Resolution confirmed: ........../........./............ □ no □ unknown
□ completely □ partial □ unknown

12. Sequelae after 1 year (± 3 months): □ yes □ no □ unknown
If yes, describe .................................................................

Risk Factors
13. Did pt. experience thrombosis before: □ yes □ no □ unknown
If yes, date of 1. thrombosis: ........../........./............ □ unknown
Location of 1. thrombosis: ................................................................. □ unknown
Prophylactic antithrombotic treatment after 1. thrombosis: □ yes □ no □ unknown
If yes, medication: .................................................................
Completed: □ yes □ no □ unknown
If yes, date of completion: ………/………../………………..…... □ unknown

### 14. Disposition:
Parents or siblings with thrombosis: □ yes □ no □ unknown
Documented inherited thrombophilia in parents or siblings: □ yes □ no □ unknown
If yes, what: .................................................................

### 15. Underlying cancer:
□ yes □ no □ unknown
If yes, diagnosis: □ leukemia/lymphoma □ CNS tumor □ other
Protocol of treatment: ................................................................. □ unknown
Phase of treatment during thrombosis: ................................................................. □ unknown
Treatment with asparaginase by the occurrence of thrombosis: □ yes □ no □ unknown
Last dose of asparaginase before thrombosis: ………/………../…………
Type of asparaginase:
□ Erwinase □ E. coli asparaginase □ PEG asparaginase □ unknown
Asparaginase stopped/decreased dose due to thrombosis? □ yes □ no □ unknown

### 16. Treatment by occurrence of thrombosis:
Steroids: □ yes □ no □ unknown
(□ prednisolone □ prednisone □ dexamethasone □ other)
TPN: □ yes □ no □ unknown
Oral contraceptive: □ yes □ no □ unknown

### 17. Infection by the time of admission:
□ yes □ no □ unknown
Type: ................................................................. □ unknown
Antibiotic treatment: □ yes □ no □ unknown
Fever >37.5: □ yes □ no □ unknown

### 18. CVL:
□ yes □ no □ unknown
Date of the last insertion: ………/………../………………..…... □ unknown
Type: □ subcutane port □ extern tunneled □ extern untunneled □ unknown
Location: □ yes □ unknown
If yes,
□ right-sided □ OE
□ left-sided □ UE
Vein: ................................................................. □ unknown
CVL removed: □ yes □ no □ unknown
Cause:
□ thrombosis □ infection □ other
19. Arterial catheter: □ yes □ no □ unknown
Date of insertion: ..…/……/…………………………... □ unknown
Artery: ………………………………………………… □ unknown

20. Risk factors within 3 months | yes | no | unknown
---|---|---|---
Surgery
Immobilization (≥4 days)
Trauma

21. Other underlying diseases: □ yes □ no □ unknown
If yes, describe: ………………………………………………………………………

22. Thrombophilia:
No work-up: □ yes → end of scheme

<table>
<thead>
<tr>
<th>Tested</th>
<th>yes</th>
<th>no</th>
<th>unknown</th>
</tr>
</thead>
<tbody>
<tr>
<td>Protein C</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Protein S</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Antithrombin</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Fibrinogen</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Lupus anticoagulant</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Cardiolipin antibodies IgM</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Cardiolipin antibodies IgG</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Beta-2-glycoprotein-1 IgM</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Beta-2-glycoprotein-1 IgG</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Activated protein C resistance</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Factor V mutation Leiden G1691A</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Factor II mutation G20210A</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Homocysteine</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Lipoprotein(a)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Factor VIII</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Documented defect: □ yes □ no □ unknown
If yes, describe: ………………………………………………………………………..